Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy

Oncogene

Volumn 35, Issue 3, 2016, Pages 314-322

  Adapala, R K ^a,b   Thoppil, R J ^a,b   Ghosh, K ^c,d   Cappelli, H C ^a,b   Dudley, A C ^d,e   Paruchuri, S ^f   Keshamouni, V ^g   Klagsbrun, M ^d   Meszaros, J G ^a,b   Chilian, W M ^a,b   Ingber, D E ^d,h   Thodeti, C K ^a,b,d  

^a Northeast Ohio Medical University   (United States)

^b KENT STATE UNIVERSITY   (United States)

^c University of California ^*  (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF AKRON   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; LEUCINE; N-(1-((4-(2-(((2,4-DICHLOROPHENYL)SULFONYL)AMINO)-3-HYDROXYPROPANOYL)-1-PIPERAZINYL)CARBONYL)-3-METHYLBUTYL)-1-BENZOTHIOPHENE-2-CARBOXAMIDE; SULFONAMIDE; TRPV4 PROTEIN, MOUSE; VANILLOID RECEPTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CALCIUM SIGNALING; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANIMALS; CALCIUM SIGNALING; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUCINE; MICE; NEOVASCULARIZATION, PATHOLOGIC; SULFONAMIDES; TRPV CATION CHANNELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84955737393     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.83     Document Type: Article

References (57)

1. Fukumura D, Jain RK. Imaging angiogenesis and the microenvironment. APMIS 2008; 116: 695-715.
2. Jain RK. Taming vessels to treat cancer. Sci Am 2008; 298: 56-63.
3. Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010; 13: 16-28.
4. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
5. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
6. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
7. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007; 13: 223-230.
8. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003; 2: S127-S133.
9. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007; 74: 72-84.
10. Jain RK, Carmeliet P. SnapShot: tumor angiogenesis. Cell 2012; 149: 1408-1408 e1401.
11. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21: 82-91.
12. Ingber DE. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res 2002; 91: 877-887.
13. Ingber DE, Prusty D, Sun Z, Betensky H, Wang N. Cell shape, cytoskeletal mechanics, and cell cycle control in angiogenesis. J Biomech 1995; 28: 1471-1484.
14. Mammoto A, Connor KM, Mammoto T, Yung CW, Huh D, Aderman CM et al. A mechanosensitive transcriptional mechanism that controls angiogenesis. Nature 2009; 457: 1103-1108.
15. Mammoto A, Mammoto T, Ingber DE. Rho signaling and mechanical control of vascular development. Curr Opin Hematol 2008; 15: 228-234.
16. Thodeti CK, Matthews B, Ravi A, Mammoto A, Ghosh K, Bracha AL et al. TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrin-to-integrin signaling. Circ Res 2009; 104: 1123-1130.
17. Ingber DE. Integrins, tensegrity, and mechanotransduction. Gravit Space Biol Bull 1997; 10: 49-55.
18. Paszek MJ, Weaver VM. The tension mounts: mechanics meets morphogenesis and malignancy. J Mammary Gland Biol Neoplasia 2004; 9: 325-342.
19. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005; 8: 241-254.
20. Ghosh K, Thodeti CK, Dudley AC, Mammoto A, Klagsbrun M, Ingber DE. Tumorderived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc Natl Acad Sci USA 2008; 105: 11305-11310.
21. Martinac B. Mechanosensitive ion channels: molecules of mechanotransduction. J Cell Sci 2004; 117: 2449-2460.
22. Matthews BD, Thodeti CK, Tytell JD, Mammoto A, Overby DR, Ingber DE. Ultrarapid activation of TRPV4 ion channels by mechanical forces applied to cell surface beta1 integrins. Integr Biol (Camb) 2: 435-442.
23. Sukharev S, Corey DP. Mechanosensitive channels: multiplicity of families and gating paradigms. Sci STKE 2004; 2004: re4.
24. Alessandri-Haber N, Dina OA, Joseph EK, Reichling DB, Levine JD. Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia. J Neurosci 2008; 28: 1046-1057.
25. Alessandri-Haber N, Dina OA, Yeh JJ, Parada CA, Reichling DB, Levine JD. Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat. J Neurosci 2004; 24: 4444-4452.
26. Lee HS, Millward-Sadler SJ, Wright MO, Nuki G, Salter DM. Integrin and mechanosensitive ion channel-dependent tyrosine phosphorylation of focal adhesion proteins and beta-catenin in human articular chondrocytes after mechanical stimulation. J Bone Miner Res 2000; 15: 1501-1509.
27. Shakibaei M, Mobasheri A. Beta1-integrins co-localize with Na, K-ATPase, epithelial sodium channels (ENaC) and voltage activated calcium channels (VACC) in mechanoreceptor complexes of mouse limb-bud chondrocytes. Histol Histopathol 2003; 18: 343-351.
28. Wilson PD, Geng L, Li X, Burrow CR. The PKD1 gene product, "polycystin-1," is a tyrosine-phosphorylated protein that colocalizes with alpha2beta1-integrin in focal clusters in adherent renal epithelia. Lab Invest 1999; 79: 1311-1323.
29. Hartmannsgruber V, Heyken WT, Kacik M, Kaistha A, Grgic I, Harteneck C et al. Arterial response to shear stress critically depends on endothelial TRPV4 expression. PLoS One 2007; 2: e827.
30. Dudley AC, Khan ZA, Shih SC, Kang SY, Zwaans BM, Bischoff J et al. Calcification of multipotent prostate tumor endothelium. Cancer Cell 2008; 14: 201-211.
31. Adapala RK, Talasila PK, Bratz IN, Zhang DX, Suzuki M, Meszaros JG et al. PKCalpha mediates acetylcholine-induced activation of TRPV4-dependent calcium influx in endothelial cells. Am J Physiol Heart Circ Physiol 2011; 301: H757-H765.
32. Liedtke W. TRPV4 plays an evolutionary conserved role in the transduction of osmotic and mechanical stimuli in live animals. J Physiol 2005; 567: 53-58.
33. Mendoza SA, Fang J, Gutterman DD, Wilcox DA, Bubolz AH, Li R et al. TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress. Am J Physiol Heart Circ Physiol 2010; 298: H466-H476.
34. Ingber DE, Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J Cell Biol 1989; 109: 317-330.
35. Brackenbury WJ, Djamgoz MB. Activity-dependent regulation of voltage-gated Na+ channel expression in Mat-LyLu rat prostate cancer cell line. J Physiol 2006; 573: 343-356.
36. Fraser SP, Ozerlat-Gunduz I, Brackenbury WJ, Fitzgerald EM, Campbell TM, Coombes RC et al. Regulation of voltage-gated sodium channel expression in cancer: hormones, growth factors and auto-regulation. Philos Trans R Soc Lond B Biol Sci 2014; 369: 20130105.
37. Baylie RL, Brayden JE. TRPV channels and vascular function. Acta Physiol (Oxf) 2011; 203: 99-116.
38. Xu H, Fu Y, Tian W, Cohen DM. Glycosylation of the osmoresponsive transient receptor potential channel TRPV4 on Asn-651 influences membrane trafficking. Am J Physiol Renal Physiol 2006; 290: F1103-F1119.
39. Adapala RK, Thoppil RJ, Luther DJ, Paruchuri S, Meszaros JG et al. TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals. J Mol Cell Cardiol 2013; 54: 45-52.
40. Gradilone SA, Masyuk AI, Splinter PL, Banales JM, Huang BQ et al. Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. Proc Natl Acad Sci USA 2007; 104: 19138-143.
41. Troidl C, Troidl K, Schierling W, Cai WJ, Nef H et al. Trpv4 induces collateral vessel growth during regeneration of the arterial circulation. J Cell Mol Med 2009; 13: 2613-2621.
42. Hu F, Zhu W, Wang L. MicroRNA-203 up-regulates nitric oxide expression in temporomandibular joint chondrocytes via targeting TRPV4. Arch Oral Biol 2013; 58: 192-199.
43. Ren XD, Kiosses WB, Schwartz MA. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. Embo J 1999; 18: 578-585.
44. Tzima E, del Pozo MA, Shattil SJ, Chien S, Schwartz MA. Activation of integrins in endothelial cells by fluid shear stress mediates Rho-dependent cytoskeletal alignment. Embo J 2001; 20: 4639-4647.
45. Fiorio Pla A, Ong HL, Cheng KT, Brossa A, Bussolati B, Lockwich T et al. TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling. Oncogene 2012; 31: 200-212.
46. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175: 409-416.
47. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288.
48. Cuevas I, Boudreau N. Managing tumor angiogenesis: lessons from VEGF-resistant tumors and wounds. Adv Cancer Res 2009; 103: 25-42.
49. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-427.
50. Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AM et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010; 16: 3618-3627.
51. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012; 7: 383-388.
52. di Tomaso E, London N, Fuja D, Logie J, Tyrrell JA, Kamoun W et al. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One 2009; 4: e5123.
53. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-1121.
54. Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2012; 2: a006486.
55. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
56. Liu J, Liao S, Huang Y, Samuel R, Shi T, Naxerova K et al. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 2011; 17: 3638-3648.
57. Thodeti CK, Massoumi R, Bindslev L, Sjolander A. Leukotriene D4 induces association of active RhoA with phospholipase C-gamma1 in intestinal epithelial cells. Biochem J 2002; 365: 157-163.